68 results match your criteria: " Children's Mercy Hospital[Affiliation]"
Impact of an Acute Care Surgery Clinical Pathway on Patient Outcomes in Acute Appendicitis.
Surg Infect (Larchmt)
November 2024
Department of Surgery, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Article Synopsis
- Acute care surgery (ACS) was implemented at a medical facility to improve the surgical treatment and management of acute appendicitis (AA) by creating a standardized perioperative clinical pathway.
- A study compared patient outcomes before (2016-2018) and after (2018-2020) implementing this pathway, analyzing 492 patients and focusing on hospital length of stay (LOS) as the primary outcome.
- Results showed a significant reduction in LOS (31.2 vs. 50.4 hours), quicker transition times from CT scans to surgery, reduced opioid use, and improved discharge processes in the post-implementation group, indicating overall enhanced surgical efficiency and care.
Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.
N Engl J Med
October 2024
From Université Paris Cité, INSERM Unité 970, Paris Institute for Transplantation and Organ Regeneration (M.S., A.S., M. Raynaud, V.G., G.D., D.Y., J.H., C. Legendre, O.A., C. Lefaucheur, A.L.), the Department of Pathology, Bichat Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) (A.S.), the Kidney Transplant Department (G.D., C. Lefaucheur) and the Department of Pathology (J. Verine), Saint-Louis Hospital, AP-HP, the Department of Pathology, Necker Hospital, AP-HP (M. Rabant), the Division of Pediatric Nephrology, Necker Hospital, AP-HP, Université Paris Cité (O. Boyer), the Department of Kidney Transplantation, Necker Hospital, AP-HP (M.T., C. Legendre, D.A., O.A., A.L.), and the Division of Pediatric Nephrology, Robert Debré Hospital, AP-HP (J.H.), Paris, the Departments of Pediatric Nephrology (M.F.) and Nephrology (M.L.Q.), Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, the Pediatric Nephrology Department, Hôpital Universitaire Mère-Enfant, Hospices Civils de Lyon (HCL) (A.-L.S.-L.), and the Department of Transplantation, Edouard Herriot University Hospital, HCL, University of Lyon I (E.M.), Lyon, the Department of Nephrology-Dialysis-Transplantation, CHU de Toulouse, Toulouse (A.B., N.K.), Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Unité Mixte de Recherche 1064, Institute of Urology-Nephrology Transplantation of the University Hospital of Nantes, Nantes (R.D., M.G., P.-A.G., S.B.), and the Departments of Pathology (B.C.) and Nephrology, Transplantation, Dialysis, and Apheresis (L.C.), CHU Bordeaux, Bordeaux - all in France; the Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health (B.C.A.), and the Department of Pathology, University of Wisconsin (A.A., W.Z.) - both in Madison; Pediatric Nephrology, David Geffen School of Medicine at UCLA, UCLA Mattel Children's Hospital (P.W.), and Cedars-Sinai Comprehensive Transplant Center (E.H.) - both in Los Angeles; the Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Hospital, Seattle (J.S.); the Division of Pediatric Nephrology, Emory University School of Medicine, Children's Pediatric Institute, Atlanta (R.G.); the Division of Pediatric Nephrology, University of Kansas City, Children's Mercy Hospital, Kansas City, MO (B.A.W.); the Division of Pediatric Nephrology and Hypertension, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis (R.S.Z.); the Acute Dialysis Units, Pediatric Kidney Transplant, Medical University of South Carolina, Charleston (K.T.); the Division of Pediatric Nephrology, Hypertension, and Apheresis, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis (V.R.D., R.S.D.); the Department of Pediatrics, Robert Wood Johnson Medical School at Rutgers University, New Brunswick, NJ (V.R.D.); the Department of Pediatrics I, University Children Hospital Heidelberg, Heidelberg (B.T.), and the Department of Nephrology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Berlin Institute of Health, Berlin (R.A.C., K.B.) - both in Germany; the Division of Abdominal and Transplantation Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals (T.B.), and the Division of Transplantation Immunology, University Hospital of Geneva (J. Villard), Geneva, and the Division of Clinical Pharmacology, Department of Medicine, and the Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne (F.R.G.) - all in Switzerland; and the Department of Nephrology and Kidney Transplantation, Vall d'Hebrón University Hospital, Barcelona (O. Bestard).
Background: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is unclear.
Methods: We conducted a cohort study that included kidney-transplant recipients from more than 30 transplantation centers in Europe and North America who had undergone allograft biopsy between 2004 and 2023.
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.
Clin Cancer Res
December 2024
Division of Pediatric Hematology/Oncology, Duke University, Durham, North Carolina.
Article Synopsis
- - A Phase II trial was conducted to evaluate the combination of gemcitabine and nab-paclitaxel for treating recurrent osteosarcoma in patients aged 12-30, with an emphasis on assessing progression-free survival and identifying potential biomarkers.
- - Eighteen patients participated, showing a 28% progression-free survival rate after four months, with some experiencing partial responses but facing dose reductions and toxicities.
- - The study concluded that the gemcitabine and nab-paclitaxel combination has comparable effectiveness and toxicity to previous treatments with gemcitabine and docetaxel, while highlighting the potential for using circulating tumor cells and circulating tumor DNA as response biomarkers in future research.
ACTION-ARC Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Adverse Event Definitions-2023.
ASAIO J
November 2024
Division of Cardiology, Stanford University School of Medicine, Palo Alto, California.
Adverse events (AEs) experienced by children and adults with congenital heart disease (CHD) on ventricular assist devices (VADs) are sometimes unique to these populations. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation. Data from the ACTION registry and adjudication committee were used to adapt general mechanical circulatory support ARC definitions.
View Article and Find Full Text PDFVitamin D and metabolic bone disease in prolonged continuous kidney replacement therapy: a prospective observational study.
BMC Nephrol
August 2024
Department of Pediatrics, Division of Pediatric Nephrology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates Avenue, Suite 245, Houston, TX, USA.
Background: Complications of prolonged continuous kidney replacement therapy (CKRT) have not been well described. Our objective was to describe mineral metabolism and bone findings in children who required prolonged CKRT.
Methods: In this single center prospective observational study, we enrolled 37 patients who required CKRT for ≥ 28 days with regional citrate anticoagulation.
Feasibility of adolescent contraceptive care in the pediatric emergency department: A pilot randomized controlled trial.
Acad Emerg Med
November 2024
Department of Pediatrics, Division of Emergency Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Background: This study assessed feasibility constructs of adolescent contraceptive care in the pediatric emergency department (PED), including contraception initiation.
Methods: We conducted a randomized trial in two PEDs with pregnancy-capable adolescents aged 15-18 years who were assigned to enhanced usual care (usual) or same-day initiation (same day). All received counseling and clinic referral, but same-day participants could also receive contraception in the PED.
The use and timing of angioembolization in pediatric blunt liver and spleen injury.
J Trauma Acute Care Surg
June 2024
From the Pediatric Trauma Center, University of Texas-Austin Dell Medical School (J.A.N., N.M.G., K.A.L.), Dell Children's Medical Center of Central Texas, Austin, Texas; Division of Trauma, Phoenix Children's Hospital, Arizona (D.M.N.), Phoenix, Arizona; Children's Hospital of Orange County Research Institute (L.W.S., M.L., R.S.), Orange, California; Division of Trauma Services, Dallas Children's Medical Center (M.R., A.A.), Dallas, Texas; University of Miami School of Medicine (A.S.C.) Miami; Division of Pediatric Surgery, Nemours Children's Healthcare (R.W.L.), Jacksonville, Florida; Department of Surgery (J.J.), Oklahoma Children's Hospital, Oklahoma City, Oklahoma; Department of Surgery (R.T.M.), Arkansas Children's Hospital, Little Rock, Arkansas; Division of Pediatric Surgery (J.W.E.), Le Bonheur Children's Hospital, Memphis, Tennessee; Department of Pediatric Surgery (T.A.P.), Akron Children's Hospital, Akron, Ohio; Department of General Surgery, Children's Mercy Hospital (S.D.S.P.), Kansas City, Missouri; Department of Pediatric Surgery, Emory University School of Medicine (A.M.B.), Atlanta, Georgia; and Division of Pediatric Surgery, University of Wisconsin School of Medicine and Public Health (C.M.L.), Madison, Wisconsin.
Article Synopsis
- * A study analyzed data from 1,004 pediatric patients across 10 trauma centers, finding that only 3% underwent AE, with some patients experiencing failed NOM needing further intervention.
- * Results indicated that AE can effectively salvage splenic injuries (100% successful), but it was typically used later in the treatment process, highlighting its limited application in pediatric trauma cases.
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
Circulation
December 2023
Heart Centre, Department of Cardiology (A.T.B., K.V.V.L., P.J.P., A.A.M.W., C.v.d.W.), Amsterdam UMC Location AMC, University of Amsterdam, The Netherlands.
Background: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia.
Methods: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy.
Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age.
Antimicrob Agents Chemother
November 2023
Division of Infectious Diseases, Children's Hospital of Orange County, Orange County, California, USA.
Antimicrobial resistance increases infection morbidity in both adults and children, necessitating the development of new therapeutic options. Telavancin, an antibiotic approved in the United States for certain bacterial infections in adults, has not been examined in pediatric patients. The objectives of this study were to evaluate the short-term safety and pharmacokinetics (PK) of a single intravenous infusion of telavancin in pediatric patients.
View Article and Find Full Text PDFEat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal.
N Engl J Med
June 2023
From the Larner College of Medicine, University of Vermont, Burlington (L.W.Y.); the Departments of Biostatistics (S.T.O., Z.H., J.Y.L.) and Pediatrics (J.N.S.), University of Arkansas for Medical Sciences, Little Rock; the University of Cincinnati College of Medicine and Perinatal Institute and the Division of Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati (S.L.M., W.R., J.M.M.), the Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland (M.C.), and the Department of Pediatrics, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus (E.F.B.); the Institutional Development Awards Program of the States Pediatric Clinical Trials Network, Environmental Influences on Child Health Outcomes (ECHO) Program, National Institutes of Health, Rockville (A.E.S.), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda (A.A.B., R.D.H., M.C.W.) - both in Maryland; the Social, Statistical, and Environmental Sciences Unit, RTI International, Research Triangle Park (A.D., M.M.C.), and the Duke Clinical Research Institute, Duke University School of Medicine (R.G.G., P.B.S.), and the Department of Pediatrics, Duke University (S.K.S.), Durham - all in North Carolina; Emory University School of Medicine, Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta (B.B.P.); the Office of Research and Sponsored Programs, Florida Gulf Coast University, Fort Myers (R.D.H.), and the Department of Pediatrics, University of South Florida, Tampa (T.W.); St. Elizabeth Healthcare, Edgewood (W.R.), and the Department of Pediatrics, University of Louisville, Louisville (S.T., L.A.D.) - both in Kentucky; the Division of Neonatology, Department of Pediatrics, ChristianaCare, Newark, DE (D.A.P.); the University of New Mexico School of Medicine, Albuquerque (J.R.M.); the Department of Pediatrics, Division of Neonatology, University of Utah School of Medicine, Salt Lake City (C.M.F.); the Department of Pediatrics, University at Buffalo, Buffalo (A.M.R.), and the University of Rochester School of Medicine and Dentistry, Rochester (J. Riccio) - both in New York; the Oklahoma University Health Sciences Center, Oklahoma City (D.W.H.); the Medical University of South Carolina, Health Shawn Jenkins Children's Hospital, Charleston (J. Ross), and the Department of Pediatrics, Spartanburg Regional Medical Center, Spartanburg (J.B.) - both in South Carolina; the Section on Newborn Medicine, Pennsylvania Hospital (K.M.P.), and the Hospital of the University of Pennsylvania (L.C.), Philadelphia; the Kapiolani Medical Center for Women and Children, Honolulu (K.W.R., A.); the Department of Pediatrics, University of Mississippi Medical Center, Jackson (L.T.); Winchester Hospital, Winchester, MA (K.R.M.); the Department of Pediatrics, University of Kansas Medical Center (K.D.), and Children's Mercy Hospital (J.W.) - both in Kansas City, MO; Sanford Health, Sioux Falls, SD (J.R.W.); Tulane University School of Medicine, New Orleans (M.P.H.); and the University of Nebraska Medical Center, Omaha (S.N.).
Background: Although clinicians have traditionally used the Finnegan Neonatal Abstinence Scoring Tool to assess the severity of neonatal opioid withdrawal, a newer function-based approach - the Eat, Sleep, Console care approach - is increasing in use. Whether the new approach can safely reduce the time until infants are medically ready for discharge when it is applied broadly across diverse sites is unknown.
Methods: In this cluster-randomized, controlled trial at 26 U.
Quantification of Free and Total Carnitine in Serum Using Liquid Chromatography Tandem Mass Spectrometry.
Methods Mol Biol
September 2022
Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO, USA.
L-carnitine is a crucial component for transporting long-chained fatty acids from the cytosol into the mitochondrial matrix for fatty acid oxidation. During this process, carnitine forms numerous acylcarnitines before being recycled into the cytosol. Abnormal levels of free carnitine, total carnitine, and acylcarnitines in serum can be indicative of a metabolic disorder before symptoms are present.
View Article and Find Full Text PDFTandem Mass Spectrometry for the Analysis of Plasma/Serum Acylcarnitines for the Diagnosis of Certain Organic Acidurias and Fatty Acid Oxidation Disorders.
Methods Mol Biol
September 2022
Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO, USA.
Acylcarnitines are formed in the mitochondria by esterification between carnitine and acyl-CoAs. This occurs enzymatically via carnitine acyltransferases. Specific acylcarnitines accumulate as a result of various organic acidurias and fatty acid oxidation disorders, and, thus, acylcarnitines profiles are used for the diagnosis of these disorders.
View Article and Find Full Text PDFScreening for pediatric abusive head trauma: Are three variables enough?
Child Abuse Negl
March 2022
Department of Public Health Sciences, Penn State College of Medicine, 700 HMC Crescent Road, Hershey, PA 17033, USA. Electronic address:
Background: The PediBIRN 4-variable clinical decision rule (CDR) detects abusive head trauma (AHT) with 96% sensitivity in pediatric intensive care (PICU) settings. Preliminary analysis of its performance in Pediatric Emergency Department settings found that elimination of its fourth predictor variable enhanced screening accuracy.
Objective: To compare the AHT screening performances of the "PediBIRN-4" CDR vs.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
April 2022
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting in lower nonrelapse mortality and increased survival.
View Article and Find Full Text PDFTriiodothyroacetic Acid Cross-Reacts With Measurement of Triiodothyronine (T3) on Various Immunoassay Platforms.
Am J Clin Pathol
February 2022
Department of Pathology, Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA.
Objectives: Thyroid hormone analog 3,5,3'-triiodothyroacetic acid (TRIAC) is effective in reducing the hypermetabolism in monocarboxylate transporter 8 (MCT8)-deficient individuals. Because of the structural similarity between TRIAC and 3,3',5'-triiodothyronine (T3), we sought to investigate the degree of cross-reactivity of TRIAC with various commercially available total and free T3 assays.
Methods: Varying concentrations (50-1,000 ng/dL) of TRIAC (Sigma Aldrich) were added to pooled serum and assayed for total T3 (TT3) and free T3 (FT3) on the following platforms: e602 (Roche Diagnostics), Architect (Abbott Diagnostics), Centaur (Siemens Healthcare Diagnostics), IMMULITE (Siemens Healthcare Diagnostics), DxI (Beckman Coulter), and Vitros (Ortho Clinical Diagnostics).
Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B.
J Pediatr Gastroenterol Nutr
August 2021
Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Objective: Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades. On the basis of promising results of a pilot study, we conducted a randomized, controlled, multicenter study to evaluate the efficacy and safety of antiviral therapy in children and adolescents with immune-tolerant CHB.
Methods: Fifty-nine children aged 3 to <18 years hepatitis B e antigen-positive with an HBV DNA titer >20,000 IU/mL and persistently normal alanine aminotransferase levels were randomized to 56 weeks of antiviral therapy with an oral nucleoside analogue [entecavir or lamivudine], combined with subcutaneous peginterferon alfa-2a from week 8, or 80 weeks of untreated observation.
Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children's Oncology Group.
Cancer
January 2021
Division of Haematology/Oncology, Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Background: To the authors' knowledge, information regarding whether daily bathing with chlorhexidine gluconate (CHG) reduces central line-associated bloodstream infection (CLABSI) in pediatric oncology patients and those undergoing hematopoietic stem cell transplantation (HCT) is limited.
Methods: In the current multicenter, randomized, double-blind, placebo-controlled trial, patients aged ≥2 months and <22 years with cancer or those undergoing allogeneic HCT were randomized 1:1 to once-daily bathing with 2% CHG-impregnated cloths or control cloths for 90 days. The primary outcome was CLABSI.
Purpose: Ewing Sarcoma Family of Tumors (ESFT), the second most common pediatric osseous malignancy, are characterized by the pathognomonic chromosomal translocation. Outside of tumor biopsy, no clinically relevant ESFT biomarkers exist. Additionally, tumor burden assessment at diagnosis, monitoring of disease responsiveness to therapy, and detection of disease recurrence are limited to radiographic imaging.
View Article and Find Full Text PDFComparing directly measured versus mathematically calculated free serum 25-hydroxy vitamin D level in children.
J Bone Miner Metab
March 2020
Division of Nephrology, Children's Mercy Hospital, University of Missouri at Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.
Introduction: 25-Hydroxy vitamin D (25(OH)D) is essential for calcium homeostasis and bone metabolism. The majority of serum 25(OH)D is bound to vitamin D-binding protein (VDBP) (~ 85%) and to albumin (~ 15%), with only a miniscule amount circulating as free 25(OH)D. Free 25(OH)D can be calculated mathematically by Bikle method from the concentrations of total 25(OH)D, VDBP, and albumin or measured directly by ELISA.
View Article and Find Full Text PDFInterrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies.
Am J Psychiatry
March 2019
The Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston (Yu, Illmann, Osiecki, Smoller, Pauls, Neale, Scharf); the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Mass. (Yu, Neale, Scharf); the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles (Sul, Huang, Zelaya, Ophoff, Freimer, Coppola); the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Sul, Huang, Zelaya, Freimer, Coppola); the Department of Molecular Biology and Genetics, Democritus University of Thrace, Xanthi, Greece (Tsetsos); the Department of Biological Sciences, Purdue University, West Lafayette, Ind. (Tsetsos, Paschou); deCODE Genetics/Amgen, Reykjavik, Iceland (Nawaz, H. Stefansson, K. Stefansson); the Bioinformatics Interdepartmental Program, University of California, Los Angeles (Huang, Zelaya); the Department of Psychiatry, University of California, San Francisco (Darrow); the Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco (Hirschtritt, Willsey); the Department of Psychiatry, Massachusetts General Hospital, Boston (Greenberg, Roffman, Buckner); the Clinic of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany (Muller-Vahl); the Institute of Human Genetics, Hannover Medical School, Hannover, Germany (Stuhrmann); McGill University Health Center, University of Montreal, McGill University Health Centre, Montreal (Dion); the Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal (Rouleau); the Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna (Aschauer, Stamenkovic); Biopsychosocial Corporation, Vienna (Aschauer, Schlögelhofer); University Health Network, Youthdale Treatment Centres, and University of Toronto, Toronto (Sandor); the Krembil Research Institute, University Health Network, Hospital for Sick Children, and University of Toronto, Toronto (Barr); Johns Hopkins University School of Medicine, Baltimore (Grados, Singer); the Institute of Human Genetics, University Hospital Bonn, University of Bonn Medical School, Bonn, Germany (Nöthen); the Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (Hebebrand, Hinney); the Yale Child Study Center and the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (King, Fernandez); the Institute of Medical Chemistry, Molecular Biology, and Pathobiochemistry, Semmelweis University, Budapest, Hungary (Barta); Vadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary (Tarnok, Nagy); the Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany (Depienne); Sorbonne Universités, UPMC Université Paris 06, UMR S 1127, CNRS UMR 7225, ICM, Paris (Depienne, Worbe, Hartmann); French Reference Centre for Gilles de la Tourette Syndrome, Groupe Hospitalier Pitié-Salpêtrière, Paris (Worbe, Hartmann); Assistance Publique-Hôpitaux de Paris, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris (Worbe, Hartmann); Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York (Budman); Child Neuropsychiatry, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy (Rizzo); the Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Lyon); the Department of Psychiatry, University of Utah, Salt Lake City (McMahon); Children's Mercy Hospital, Kansas City, Mo. (Batterson); the Department of Psychiatry, University Medical Center Groningen and Rijksuniversity Groningen, and Drenthe Mental Health Center, Groningen, the Netherlands (Cath); the Department of Neurology, Fixel Center for Neurological Diseases, McKnight Brain Institute, University of Florida, Gainesville (Malaty, Okun); Pennsylvania State University College of Medicine, Hershey (Berlin); Marquette University and University of Wisconsin-Milwaukee, Milwaukee (Woods); Tripler Army Medical Center and University of Hawaii John A. Burns School of Medicine, Honolulu (Lee); Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston (Jankovic); the Division of Psychiatry, Department of Neuropsychiatry, University College London (Robertson); the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati (Gilbert); Children's Hospital of Philadelphia, Philadelphia (Brown); the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami (Coffey); the Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Dietrich, Hoekstra); University of Iowa Carver College of Medicine, Iowa City (Kuperman); the Department of Pediatrics, University of Washington, Seattle (Zinner); the Department of Pediatrics, Landspitalinn University Hospital, Reykjavik, Iceland (Luðvigsson, Thorarensen); the Faculty of Medicine, University of Iceland, Reykjavík, Iceland (Sæmundsen, Stefansson); the State Diagnostic and Counselling Centre, Kópavogur, Iceland (Sæmundsen); the Department of Genetics and the Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (Atzmon, Barzilai); the Department of Human Biology, Haifa University, Haifa, Israel (Atzmon); the Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany (Wagner); the Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany (Moessner); SUNY Downstate Medical Center Brooklyn, New York (C.M. Pato, M.T. Pato, Knowles); the Athinoula A. Martinos Center for Biomedical Research, Department of Radiology, Massachusetts General Hospital, Charlestown (Roffman, Buckner); the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Smoller); the Center for Brain Science and Department of Psychology, Harvard University, Cambridge, Mass. (Buckner); the Institute for Neurodegenerative Diseases, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco (Willsey); the Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers, the State University of New Jersey, Piscataway (Tischfield, Heiman); the Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, Amsterdam (Posthuma); the Division of Genetic Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tenn. (Cox, Davis); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston (Neale); the Department of Psychiatry, Genetics Institute, University of Florida, Gainesville (Mathews); and the Department of Neurology, Brigham and Women's Hospital, and the Department of Neurology, Massachusetts General Hospital, Boston (Scharf).
Article Synopsis
- The study investigates the genetic basis of Tourette's syndrome through a genome-wide association study (GWAS) involving a large sample of case subjects and controls to identify shared genetic factors and predict tic severity.
- A significant genetic association was found with the FLT3 gene on chromosome 13, but it was not confirmed in a follow-up study; nonetheless, most of the heritability was linked to genetic variants in conserved regions.
- The findings suggest that genetic risk scores for Tourette's are linked to the severity of tics and are higher in individuals with a family history of tic disorders, indicating a potential genetic influence on the manifestation of the syndrome.
25-Hydroxyvitamin D Testing: Immunoassays Versus Tandem Mass Spectrometry.
Clin Lab Med
September 2018
Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, University of Missouri School of Medicine, 2401 Gillham Road, Kansas City, MO 64108, USA. Electronic address:
Vitamin D has been associated with many health conditions. Because of widespread deficiency in the general population, laboratory testing of vitamin D has increased exponentially in recent years. Currently, 25-hydroxyvitamin D (25[OH]D) is considered the best marker of vitamin D status.
View Article and Find Full Text PDFVitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.
Pediatr Nephrol
November 2018
Johns Hopkins University, Baltimore, MD, 21218, USA.
Background: 25-Hydroxyvitamin D (25OHD) deficiency is common in children with chronic kidney disease (CKD). It has been associated with an increased risk for anemia in both healthy US children and in adults with CKD. This association has not been explored in children with CKD.
View Article and Find Full Text PDFIntensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing.
Pediatr Res
September 2018
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, MO, USA.
TRPV1 and the MCP-1/CCR2 Axis Modulate Post-UTI Chronic Pain.
Sci Rep
May 2018
Departments of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611, USA.
The etiology of chronic pelvic pain syndromes remains unknown. In a murine urinary tract infection (UTI) model, lipopolysaccharide of uropathogenic E. coli and its receptor TLR4 are required for post-UTI chronic pain development.
View Article and Find Full Text PDFDetermination of Mycophenolic Acid and Mycophenolic Acid Glucuronide Using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS).
Curr Protoc Toxicol
February 2018
Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, Missouri.
Mycophenolic acid (MPA) is an immunosuppressant that is used in renal, liver, and heart transplantation. Due to its narrow therapeutic range, monitoring of MPA levels is essential to avoid toxicity and organ rejection. Although immunoassays are available for the determination of MPA, due to their higher specificity, mass spectrometry methods are preferred.
View Article and Find Full Text PDF